Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00660920
Other study ID # AP24534-07-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date June 2008
Est. completion date May 2016

Study information

Verified date February 2018
Source Takeda
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine the maximum tolerated dose or a recommended dose of oral AP24534 in a defined schedule in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies.


Recruitment information / eligibility

Status Completed
Enrollment 81
Est. completion date May 2016
Est. primary completion date May 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Male or Female = 18 years old

- Diagnosed hematologic malignancy (other than lymphoma) that has relapsed or is refractory to standard care or for which no standard care is available or acceptable

- Able to give written informed consent

- ECOG performance status = 2

- BSA = 1.5 m² (first cohort only)

- Minimum life expectancy of 3 months or more

- Adequate renal function defined as serum creatinine <1.5× upper limit of normal (ULN) for institution

- Adequate hepatic function (defined as: Total bilirubin <1.5 × ULN for institution; ALT and AST <2.5 × ULN for institution [<5 X ULN if liver involvement with leukemia]; Prothrombin time <1.5 × ULN)

- Ability to comply with study procedures in the Investigator's opinion

- Adequate cardiac function defined as ejection fraction (EF) >40% by any method of the investigator's choice

- Normal QTcF interval on screening ECG evaluation, defined as QTcF of <450 ms.

- For females of childbearing potential, a negative pregnancy test must be documented prior to enrollment

- Female patients who are of childbearing potential must agree to use an effective form of contraception with their sexual partners throughout participation in this study

Exclusion Criteria:

- Have had cytotoxic chemotherapy or radiotherapy within 21 days prior to entering the study, or those who have not recovered from adverse events due to agents administered more than 28 days earlier with the exception of alopecia

- Received any other investigational agents or have received an investigational agent within 14 days of starting ponatinib

- Malabsorption syndrome or other illness which could affect oral absorption

- Significant uncontrolled cardiac disease

- Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram.

- Uncontrolled hypertension (Diastolic BP >100 mmHg; Systolic >150 mmHg)

- Uncontrolled intercurrent illness

- Pregnant

- Known infection with HIV

- Autologous or allogeneic stem cell transplant < 3 months prior to enrollment; any evidence of ongoing graft versus host disease (GVHD), or GVHD requiring immunosuppressive therapy

- Another primary malignancy within the past 3 years

- Any condition or illness which, in the opinion of the investigator, would compromise patient safety or interfere with the evaluation of the safety of the drug

- Patients taking medicinal products that are known to be associated with prolongation of the QT interval on the electrocardiogram

- Major surgery (with the exception of intravenous catheter placement or bone marrow biopsy) within 14 days prior to initiating ponatinib therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ponatinib
Comparison of different dosages of drug given orally once per day.

Locations

Country Name City State
United States ARIAD Investigational Site #011 Ann Arbor Michigan
United States ARIAD Investigational Site #005 Houston Texas
United States ARIAD Investigational Site #076 Nashville Tennessee
United States ARIAD Investigational Site #048 Portland Oregon
United States ARIAD Investigational Site #075 San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Ariad Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine Maximum Tolerated Dose (MTD) or Recommended dose Determine MTD dose or a recommended dose of oral ponatinib in a defined schedule (QD) in patients with refractory or advanced chronic myelogenous leukemia and other refractory hematologic malignancies. Up to
Secondary To examine the safety of AP24534 in patients with resistant/refractory hematologic malignancies Up to 7 years
Secondary To describe the anti-tumor activity of AP24534 in patients with refractory hematologic malignancies Up to 7 years
Secondary To examine the pharmacokinetics of AP24534 Up to 2 cycles (1 cycle = 28 days)
Secondary To examine pharmacodynamic activity of AP24534 in CML and Ph + ALL patients Up to 7 years
Secondary To describe potential pharmacogenomic markers of AP24534 anti-tumor activity Up to 7 years
See also
  Status Clinical Trial Phase
Recruiting NCT05433090 - An Inpatient Advance Care Planning Intervention for Older Patients With Hematologic Malignancies N/A
Completed NCT00061620 - Phase I Study of Continuous Infusion Schedule of FMdC in Hematologic Malignancies Phase 1
Enrolling by invitation NCT02473757 - Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Not yet recruiting NCT06296368 - DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics N/A
Recruiting NCT02032446 - Umbilical Cord Derived Mesenchymal Stromal Cells For The Treatment of Severe Steroid-resistant Graft Versus Host Disease Phase 1/Phase 2
Recruiting NCT01203722 - Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies Phase 1/Phase 2
Recruiting NCT02884375 - Elderly CAncer Patient N/A
Completed NCT00780052 - Infusional C-myb ASODN in Advanced Hematologic Malignancies Phase 1
Recruiting NCT04098393 - Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation Phase 1
Recruiting NCT06028828 - Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Completed NCT04538599 - RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies Phase 1
Completed NCT03609827 - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed NCT01380756 - Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia Phase 1
Recruiting NCT05849207 - Post-Transplant Cyclophosphamide in Patients Aged >/= 70 Years Undergoing Haploidentical Transplant Phase 1
Not yet recruiting NCT05028478 - A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies Phase 1/Phase 2
Active, not recruiting NCT02494258 - A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders Phase 2
Completed NCT03212560 - Exercise Capacity and Physical Activity Levels in Newly Diagnosed Hematologic Malignant Patients
Active, not recruiting NCT02600208 - Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device Phase 2/Phase 3
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01949545 - Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment Phase 1